# US 12,180,180 B1 · 4-[4,5-bis(4-bromophenyl)-1-hexyl-1H-imidazol-2-yl]isoquinolin-3-ol as an antimicrobial compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,180 B1
- Document ID: US12180180B1
- Status: Granted
- Kind: B1
- Application number: 18/641,845
- Filed: 2024-04-22
- Granted: 2024-12-31
- Earliest claimed: 2023-11-07
- Assignees: King Faisal University
- Applicants: King Faisal University
- Inventors: Hany Mohamed Abd El-Lateef Ahmed; Mai Mostafa Khalaf Ali; Antar Ahmed Abdelhamid Ahmed
- Web page: https://patentgrep.com/patent/US12180180B1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C07D 401/14: containing three or more hetero rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

An 4-[4,5-bis(4-bromophenyl)-1-hexyl-1H-imidazol-2-yl]isoquinolin-3-ol compound, its synthesis, and its use as an antimicrobial agent.

## Claims

### Claim 1

A method of treating a microbial infection in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a 4-[4,5-bis(4-bromophenyl)-1-hexyl-1H-imidazol-2-yl]isoquinolin-3-ol compound having the formula I:
wherein the microbial infection is caused by one or more gram positive bacteria, one or more gram negative bacteria, one or more fungi, or a combination thereof; and wherein the one or more gram positive bacteria comprises Staphylococcus aureus; the one or more gram negative bacteria is selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli, and a combination thereof; and the one or more fungus comprises Candida albicans.

### Claim 2 (depends on 1)

The method of treating the microbial infection of claim 1, wherein the microbial infection is caused by Staphylococcus aureus.

### Claim 3 (depends on 1)

The method of treating the microbial infection of claim 1, wherein the microbial infection is caused by one or more gram negative bacteria selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli, and a combination thereof.

### Claim 4 (depends on 1)

The method of treating the microbial infection of claim 1, wherein the microbial infection is caused by Candida albicans.